• Clinical Insights — January Issue 2

    Welcome to the second January edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Formulation Approval Humulin® R KwikPen® (insulin human injection) – New Formulation Approval January 21, 2016 – The U.S. Food and Drug Administration approved Eli Lilly and Company’s Humulin®… Read more »

  • Clinical Insights — January Issue 1

    Welcome to the first January edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.     New Drug Approval Zurampic® (lesinurad) December 22, 2015 – The U.S. Food and Drug Administration approved Zurampic® (lesinurad) to treat high levels of uric acid in the blood… Read more »

  • RxStrategies Clinical Insights — November 2015, Issue 2

    Welcome to the second November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.     New Drug Approval Ninlaro® (ixazomib) November 20, 2015 – The U.S. Food and Drug Administration approved ixazomib (Ninlaro®, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical… Read more »

  • RxStrategies Clinical Insights — November Issue 1

    Welcome to the first November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Imlygic™ (talimogene laherparepvec) October 27, 2015 — The U.S. Food and Drug Administration approved Imlygic™ (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the… Read more »

  • RxStrategies Clinical Insights — October Issue 1

    Welcome to the first October edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Tresiba® (insulin degludec injection) September 25, 2015 — The U.S. Food and Drug Administration approved Tresiba® (insulin degludec injection) and Ryzodeg® 70/30 (insulin degludec/insulin… Read more »

  • RxStrategies Clinical Insights — September 2015 Issue 1

    Welcome to the first September edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Xuriden™ (uridine triacetate) September 4, 2015 — The U.S. Food and Drug Administration approved Xuriden™ (uridine triacetate), the first FDA-approved treatment for patients with… Read more »

  • RxStrategies Clinical Insights — August 2015 Issue 1

    Welcome to the August edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Odomzo® (sonidegib) July 24, 2015 — The U.S. Food and Drug Administration approved Odomzo® (sonidegib) to treat patients with locally advanced basal cell carcinoma that… Read more »

  • RxStrategies Clinical Insights — June/July Issue 1

    Welcome to the June/July edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Kengreal™ (cangrelor) June 22, 2015 — The U.S. Food and Drug Administration approved Kengreal™ (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood… Read more »

  • RxStrategies Clinical Insights – May 2015 Issue 2

    Welcome to May’s second edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Viberzi™ (eluxadoline) May 27, 2015 — Actavis plc announced Viberzi™ (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for… Read more »

  • RxStrategies Clinical Insights – May 2015 Issue 1

    Welcome to the May edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Kybella™ (deoxycholic acid) April 29, 2015 – The U.S. Food and Drug Administration approved Kybella™ (deoxycholic acid), a treatment for adults with moderate-to-severe fat below… Read more »